TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Grazax in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Boys and girls 5-16 years of age~* A clinical history of grass pollen induced hayfever~* Positive Skin Prick Test to Phleum pratense~* Positive specific IgE against Phleum pratense~Exclusion Criteria:~* History of seasonal hayfever symptoms (and/or asthma) caused by another allergen than Phleum pratense during or overlapping the grass pollen season~* History of perennial hayfever (and/or asthma) that needs medication due to an allergen to which the child is regularly exposed~* History of severe asthma~* Current severe atopic dermatitis

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Grazax treatment
- 2 (Type: PLACEBO_COMPARATOR): Grazax Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All Groups:~  * Must not have a fever of ≥100.4° F on the day of vaccination~ * Any underlying chronic illness must be in stable condition~ * History of varicella or residence in a VZV-endemic area for ≥30 years~* Group 1:~  * 70 years of age or older~ * Took part in the Shingles Prevention Study (SPS) (V211-004, NCT00007501) and received a single dose of Zoster Vaccine, Live ≥10 years prior to enrollment in this study~* Group 2:~  * 70 years of age or older~* Group 3:~  * 60 to 69 years of age~* Group 4:~  * 50 to 59 years of age~Exclusion Criteria:~* All Groups:~  * History of hypersensitivity reaction to any vaccine component or an anaphylactic/anaphylactoid reaction to neomycin~ * Prior history of herpes zoster~ * Pregnant or breast-feeding, or expecting to conceive within the duration of the study~ * Has been treated with immunoglobulin or any blood products, other than autologous (self-donated) blood transfusion, in the 5 months prior to vaccination~ * Received any other vaccine within 4 weeks prevaccination~ * On immunosuppressive therapy~ * Has known or suspected immune dysfunction~ * Is taking any non-topical antiviral therapy with activity against herpesviruses, including, but not limited to acyclovir, famciclovir, valacyclovir, and ganciclovir.~* Groups 2, 3, and 4:~  * Has previously received any varicella or zoster vaccine

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1: Booster Dose Participants ≥70 years of age (Type: EXPERIMENTAL): Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
- Group 2: First Dose Participants ≥70 years of age (Type: EXPERIMENTAL): Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
- Group 3: First Dose Participants ≥60 and <70 years of age (Type: EXPERIMENTAL): Herpes zoster history-negative participants ≥60 and \<70 years of age who have never received Zoster Vaccine, Live
- Group 4: First Dose Participants ≥50 and <60 years of age (Type: EXPERIMENTAL): Herpes zoster history-negative participants ≥50 and \<60 years of age who have never received Zoster Vaccine, Live

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary hyperparathyroidism~* Scheduled for parathyroid surgery~* Age \>40~* Ability to participate in all tests included in the study model~* Signed consent~Exclusion Criteria:~* Pregnancy~* Breast feeding~* Fertile woman not using contraceptives (IUD or pills)~* Impaired kidney function, GFR \< 40 ml/min~* Intolerance to Mimpara®~* Previously treated with Mimpara®~* Participating in other ongoing clinical study~* Epilepsy~* Severe hepatic impairment~* Hypotension~* Heart failure (NYHA class 3-4, symptoms with minimal exertion)~* Medication with ketoconazole (oral) or tricyclic antidepressants

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet (Type: EXPERIMENTAL): Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.~Second intervention: Parathyroid adenomectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects aged ≥6 to \<12 years~2. Clinical history of SAR (at least 2 years) with exacerbations during the study season for the relevant seasonal allergen (e.g., tree/grass pollen)~3. Demonstrated sensitivity to at least 1 seasonal allergen through positive skin prick test within 12 months prior to screening~4. A 12-hour rTNSS value ≥6 out of a possible 12 for the morning assessment at screening~5. Signed informed consent/assent form (subject and parent/caregiver/legal guardian)~Exclusion Criteria:~1. Females of childbearing potential or pregnant~2. Plans to travel outside the known pollen area for the investigational site for 24 hours or longer during the last 7 days of the run-in period.~3. History of anaphylaxis and/or other severe local reaction(s) to skin testing~4. History and evidence of acute or significant chronic sinusitis or chronic purulent post nasal drip~5. Subjects with an active pulmonary disorder or infection.~6. Subjects with posterior subcapsular cataracts or glaucoma

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- GSP 301 NS (Type: EXPERIMENTAL): Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
- GSP 301 Placebo NS (Type: PLACEBO_COMPARATOR): GSP 301 Placebo nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes patients with diabetic nephropathy in the range of micro- or macroalbuminuria~* treatment with combination of enalapril and losartan for more than one year~Exclusion Criteria:~* history of non-adherence to prescribed medication assessed by the prescribing physician~* baseline potassium \> 5.5 meq/L~* chronic kidney disease stages 4 or 5~* history or evidence of non-diabetic kidney disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ACE/ARB (Type: NO_INTERVENTION): In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
- Spironolactone/ARB (Type: ACTIVE_COMPARATOR): spironolacone 25 mg tablets added to losartan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria:~  * 6 to 16 years old~ * Diagnosis of ADHD according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM IV) confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version (SADS PL)~ * Pharmacological naïve~ * Normal intelligence as assessed by investigator~ * Each patient (and/or legally authorized patient representative where required by local law) must understand the nature of the study and must sign an Informed Consent Document.~Exclusion Criteria:~* Exclusion criteria~  * History of bipolar disorder, any history of psychosis or autism spectrum disorder~ * History of any seizure disorder~ * Significant prior or current medical conditions~ * History of alcohol or drug abuse within the past 3 months~ * Patients who are taking concurrently any of the excluded medications in the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): 0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
- OEST (Type: ACTIVE_COMPARATOR): Other Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* Undergoing FFR assessment for standard clinical indications.~* Ability to understand and willingness to sign a written informed consent.~Exclusion Criteria:~* Prior coronary artery bypass grafting (CABG).~* Extremely tortuous or calcified coronary arteries precluding intracoronary physiologic measurements. Operators may exclude subtotal or similar high-grade lesions, which in their judgment may be threatened by pressure wire placement.~* Known severe left ventricular hypertrophy (septal wall thickness at echocardiography of \>13 mm).~* Inability to receive adenosine (for example, severe reactive airway disease, marked hypotension, or advanced atrioventricular block without pacemaker).~* Recent (within 3 weeks prior to cardiac catheterization) ST-segment elevation myocardial infarction (STEMI) in any arterial distribution (not specifically target lesion).~* Culprit lesions (based on clinical judgment of the operator) for either STEMI or non-STEMI cannot be included.~* Severe cardiomyopathy (ejection fraction \<30%).~* Renal insufficiency such that an additional 12 to 20 mL of contrast would, in the opinion of the operator, pose unwarranted risk to the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: None): Entire cohort undergoes paired testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Women ages 18 and older undergoing elective surgical abortion at 5 and 0/7 to 11 and 6/7 weeks gestational age~* Use of IV sedation for pain management~* English or Spanish speaking~* Ability to give informed consent~Exclusion criteria:~* Any pre-operative use of misoprostol (typically given at 12 weeks and above in this clinic)~* Allergy to study medications: lidocaine, midazolam, fentanyl~* Known uterine anomaly~* Prior cervical surgery.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active Comparator (Type: EXPERIMENTAL): Drug: vaginal 2% Xylocaine
- standard lidocaine paracervical block (Type: OTHER): standard lidocaine paracervical block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female;~2. 18/21 (legal age to purchase tobacco at site);~3. Biochemically confirmed smoker.~Exclusion Criteria:~1. Unstable health condition;~2. Unstable medications;~3. Pregnant or nursing.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Very Low Nicotine Content Cigarettes (Type: EXPERIMENTAL): Very Low Nicotine Content Cigarettes (0.4 mg nicotine/g tobacco; 9 mg of tar): Median nicotine content, averaged across menthol and non-menthol cigarettes:
- Normal Nicotine Content Cigarettes (Type: ACTIVE_COMPARATOR): Normal (Conventional) Nicotine Content (15.8 mg nicotine/g tobacco; 9 mg of tar): Median nicotine content, averaged across menthol and non-menthol cigarettes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Voluven® for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* elective cesarean section applying spinal anesthesia~* ≥ week 37 of gestation~* Singleton pregnancy~Exclusion Criteria:~* Suspicion of any hypertensive disease~* Parturient in labor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): 500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
- Group B (Type: ACTIVE_COMPARATOR): 1000 mL Ringer's Lactate solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven mantle cell lymphoma~* Patients who are refractory to their regimen or have relapsed once, twice or up to three times and who have documented progressive disease~* Eastern Cooperative Oncology Group (ECOG) performance score 0,1, or 2~* Willing to follow pregnancy precaution~Exclusion Criteria:~* Any of the following laboratory abnormalities~* Absolute neutrophil count (ANC) \< 1,500 cells/mm\^3 (1.5 x 10\^9/L)~* Platelet count \< 60,000/mm\^3 (60 x 10\^9/L)~* Serum aspartate transaminase/serum glutamic oxaloacetic transaminase(AST/SGOT) or alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) \>3.0 x upper limit or normal (ULN), except patients with documented liver involvement by lymphoma~* Serum total bilirubin \> 1.5 x ULN, except in case of Gilbert's Syndrome and documented liver involvement by lymphoma.~* Calculated creatinine clearance (Cockcroft-Gault formula) of \< 30 mL/min~* History of active central nervous system (CNS) lymphoma within the previous 3 months~* Subjects not willing to take deep venous thrombosis (DVT) prophylaxis~* Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are sero-positive because of hepatitis B virus vaccine are eligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Lenalidomide
- Investigators choice single agent (Type: ACTIVE_COMPARATOR): Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, Fludarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Subject has a current DAS28 equal to or less than 3.2.~* Subject is currently receiving treatment with etanercept, either 25 mg twice weekly or 50 mg once weekly, for a minimum of 14 months at baseline~* Subject is currently receiving oral, sc or intramuscular methotrexate once weekly, 7.5 mg/week to 25 mg/week and at a stable dose for a minimum of 4 months at baseline.~Exclusion Criteria:~* Subject has earlier had an attempt of discontinuing etanercept for reasons of remission or low disease activity state.~* Subject has received any disease-modifying anti-rheumatic drug, other than methotrexate, within one month before baseline.~* Subject has had a dose of prednisone (or equivalent) \>7.5 mg/day or has received intra-articular, intravenous, intramuscular, or subcutaneous corticosteroid within one month of baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 50mg once weekly + methotrexate
- 2 (Type: ACTIVE_COMPARATOR): 25mg once weekly + methotrexate
- 3 (Type: PLACEBO_COMPARATOR): once weekly + methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 1 year and \</= 10 years~* Weight over 10kg~* Fever \>38 degrees C (tympanic) or history of fever in the last 24 hours~* P. falciparum parasitaemia \<500 000/µl~* Normal G6PD enzyme function~Exclusion Criteria:~* Enrolled in another study~* Evidence of severe illness/ danger signs~* Known allergy to study medications~* Haemoglobin \< 8g/dL)~* Started menstruation~* Pregnancy or breastfeeding~* Primaquine taken within the last 4 weeks~* Blood transfusion within the last 90 days~* Non-falciparum malaria co-infection

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Non-active drug
- Low dose primaquine (PQ1) (Type: EXPERIMENTAL): Lowest experimental dose of primaquine base: 0.1mg/kg
- Intermediate dose primaquine (PQ2) (Type: EXPERIMENTAL): Intermediate experimental dose of primaquine base: 0.4mg/kg
- Reference dose primaquine (PQ-R) (Type: ACTIVE_COMPARATOR): WHO-recommended dose of primaquine base: 0.75mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete